Department of Orthopaedic Surgery, Orthopaedic Oncology Service, Massachusetts General Hospital - Harvard Medical School, Boston, MA, USA.
Department of Orthopaedic Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Acta Oncol. 2020 Dec;59(12):1488-1495. doi: 10.1080/0284186X.2020.1800087. Epub 2020 Jul 30.
Predicting oncologic outcomes is essential for optimizing the treatment for patients with cancer. This review examines the feasibility of using Computed Tomography (CT) images of fat density as a prognostic factor in patients with cancer.
A systematic literature search was performed in PubMed, Embase and Cochrane up to March 2020. All studies that mentioned using subcutaneous or visceral adipose tissue (SAT and VAT, respectively) CT characteristics as a prognostic factor for patients with cancer were included. The primary endpoints were any disease-related outcomes in patients with cancer.
After screening 1043 studies, ten studies reporting a total of 23 - ten for SAT and thirteen for VAT - comparisons on survival, tumor recurrence and postsurgical infection were included. All ten studies included different types of malignancy: six localized, two metastatic disease, and two both. Five different anatomic landmarks were used to uniformly measure fat density on CT: lumbar (L)4 ( = 4), L3 ( = 2), L4-L5 intervertebral space ( = 2), L5-S1 intervertebral space ( = 1), and the abdomen ( = 1). Overall, six of ten SAT comparisons (60%) and six of thirteen VAT comparisons (46%) reported a significant ( < .05) association of increased SAT or VAT density with an adverse outcome. All remaining nonsignificant comparisons, except one, deviated in the same direction of being predictive for adverse outcomes but failed to reach significance. The median hazard ratio (HR) for the nine SAT and thirteen VAT associations where HRs were given were 1.45 (95% confidence interval [CI] 1.01-1.97) and 1.90 (95% CI 1.12-2.74), respectively. The binomial sign test and Fisher's method both reported a significant association between both SAT and VAT and adverse outcomes.
This review may support the feasibility of using SAT or VAT on CT as a prognostic tool for patients with cancer in predicting adverse outcomes such as survival and tumor recurrence. Future research should standardize radiologic protocol in prospective homogeneous series of patients on each cancer diagnosis group in order to establish accurate parameters to help physicians use CT scan defined characteristics in clinical practice.
预测肿瘤学结果对于优化癌症患者的治疗至关重要。本综述研究了使用计算机断层扫描(CT)图像中的脂肪密度作为癌症患者预后因素的可行性。
在 PubMed、Embase 和 Cochrane 上进行了系统的文献检索,检索时间截至 2020 年 3 月。所有提到将皮下或内脏脂肪组织(SAT 和 VAT)CT 特征作为癌症患者预后因素的研究均被纳入。主要终点是癌症患者的任何疾病相关结局。
筛选出 1043 项研究后,纳入了 10 项研究,共涉及 23 项 SAT 比较和 13 项 VAT 比较,涉及生存、肿瘤复发和术后感染。所有 10 项研究均涉及不同类型的恶性肿瘤:6 项局限性疾病,2 项转移性疾病,2 项均有。有 5 种不同的解剖学标志用于在 CT 上均匀测量脂肪密度:L4( = 4)、L3( = 2)、L4-L5 椎间空间( = 2)、L5-S1 椎间空间( = 1)和腹部( = 1)。总体而言,10 项 SAT 比较中有 6 项(60%)和 13 项 VAT 比较中有 6 项(46%)报告了 SAT 或 VAT 密度增加与不良结局之间存在显著关联( < .05)。除了 1 项外,其余所有无统计学意义的比较结果都朝着对不良结局具有预测作用的方向偏离,但未能达到统计学意义。9 项 SAT 相关性和 13 项 VAT 相关性中给出 HR 的中位 HR 分别为 1.45(95%置信区间 [CI] 1.01-1.97)和 1.90(95% CI 1.12-2.74)。二项符号检验和 Fisher 方法均报告 SAT 和 VAT 与不良结局之间存在显著关联。
本综述可能支持使用 CT 上的 SAT 或 VAT 作为预测癌症患者不良结局(如生存和肿瘤复发)的预后工具的可行性。未来的研究应在每个癌症诊断组的前瞻性同质患者系列中标准化放射学方案,以建立准确的参数,帮助医生在临床实践中使用 CT 扫描定义的特征。